⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885194 | 0.92 | — | — | |
| SCHEMBL23892877 | 0.85 | — | — | |
| SCHEMBL18800903 | 0.85 | TSHR (0.40) | — | |
| SCHEMBL26381296 | 0.81 | — | — | |
| SCHEMBL22952364 | 0.78 | — | — | |
| SCHEMBL20652069 | 0.78 | DNM1 (0.30) | — | |
| SCHEMBL18685446 | 0.76 | GNAI3 (0.33) | — | |
| SCHEMBL23183040 | 0.76 | TSHR (0.33) | — | |
| SCHEMBL24525753 | 0.74 | — | — | |
| SCHEMBL22423616 | 0.74 | FAAH (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121259-A1 | TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |
| WO-2021222875-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |